Invasive Ductal Carcinoma Treatment Market To Reach $15.21 Billion By 2030

Invasive Ductal Carcinoma Treatment Market Growth & Trends

The global invasive ductal carcinoma treatment market size is expected to reach USD 15.21 billion in 2030 and is projected to grow at a CAGR of 8.50% from 2025 to 2030. The market encompasses a wide range of elements that contribute to the management and care of patients diagnosed with this common form of breast cancer.

Increased awareness about breast cancer and its early detection led to more women undergoing regular screenings. The American Cancer Society reports that regular mammograms can detect breast cancer at an earlier stage when it is more treatable. This heightened awareness contributes to earlier diagnosis and increases the demand for effective IDC treatments as more cases are identified.

The government approval process involves rigorous evaluation by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies assess clinical trial data to ensure that new therapies are safe and effective before approval. For instance, in March 2024, AstraZeneca’s Truqap (capivasertib) received approval in Japan for use alongside Faslodex (fulvestrant) to treat adult patients with unresectable or recurrent breast cancer that is hormone receptor-positive, HER2-negative, and has alterations in PIK3CA, AKT1, or PTEN after they experienced disease progression following endocrine therapy.

 Request a free sample copy or view report summary: Invasive Ductal Carcinoma Treatment Market Report

Invasive Ductal Carcinoma Treatment Market Report Highlights

• Based on therapy, targeted therapy dominated the market with the largest revenue share of 65.29% in 2024. As pharmaceutical companies continue to invest in developing novel targeted agents and combination therapies, targeted therapy is expected to maintain its leading position in the IDC treatment landscape.

• Based on type, hormone receptors dominated the market with the largest revenue share of 65.33% in 2024. The growing awareness and emphasis on personalized medicine are enhancing the market for hormone receptor therapies. As healthcare providers increasingly utilize biomarker testing to tailor treatments to individual patients, identifying hormone receptor status has become crucial in treatment planning.

• Based on distribution channel, hospital pharmacies dominated the market with the largest revenue share of 45.53% in 2024. This dominance is driven by several factors, including the increasing reliance on chemotherapy and targeted therapies administered in hospital settings, where patients receive comprehensive care.

Invasive Ductal Carcinoma Treatment Market Segmentation

Grand View Research has segmented the global invasive ductal carcinoma treatment market on the basis of therapy, type, and distribution channel:

Invasive Ductal Carcinoma Treatment Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted Therapy

  • Abemaciclib

  • Ado-Trastuzumab Emtansine

  • Everolimus

  • Trastuzumab

  • Ribociclib

  • Palbociclib

  • Pertuzumab

  • Olaparib

  • Others

• Hormonal Therapy

  • Selective Estrogen Receptor Modulators (SERMs)

  • Aromatase Inhibitors

  • Estrogen Receptor Down regulators (ERDs)

• Chemotherapy

• Immunotherapy

Invasive Ductal Carcinoma Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Hormone Receptor

• HER2+

Invasive Ductal Carcinoma Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Other

Invasive Ductal Carcinoma Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Invasive Ductal Carcinoma Treatment Market

• Novartis AG

• Pfizer Inc.

• Merck KGaA

• Janssen Pharmaceuticals, Inc.

• F. Hoffmann-La Roche Ltd.

• AstraZeneca

• AbbVie Inc.

• Bristol-Myers Squibb Company

• Macrogenics, Inc.

• Celldex Therapeutics